Covishield, Covaxin Doses SCHEDULE: CONFUSION CLEARED by NITI AAYOG member Dr Vinod Kumar Paul

NITI Aayog Member (Health) Dr. Vinod Kumar Paul has today again repeated that there is absolutely no change in the schedule of Covishield and Covaxin doses. There will be two doses only for both.

Clearing the air on misinformation, he said that the information about Covishield that one dose is sufficient is absolutely wrong.

See Zee Business Live TV Streaming Below:

Briefing the media, Dr. Paul said, "Only one dose of the Covishield dose news is incorrect." India has scheduled 2 doses of Covishield.

#Covishield की केवल एक डोज लगाने वाली खबर ग़लत है

कोविशील्ड के टीकाकरण शिड्यूल में किसी तरह का कोई बदलाव नहीं हुआ है व 12 हफ्ते के बाद दूसरी डोज लेना जरूरी है

"भारत में कोविशील्ड का शिड्यूल 2 डोज का है,इसमें कोई बदलाव नहीं किया गया है"
- डॉ वी के पॉल,सदस्य (स्वास्थ्य) नीति आयोग pic.twitter.com/vofFAMQcaj

— PIB Fact Check (@PIBFactCheck) June 1, 2021

There is no change in the vaccination schedule of Covishield. Subsequently, after the first Covishield dose is administered, the second dose will be given after the gap of 12 weeks, he said.

"Covishield schedule in India is of 2 doses, no change has been made," added Dr. Paul.

The Covaxin is developed by Bharat Biotech, whereas the Covishield is developed by Serum Institute. Similarly, India has scheduled 2 doses of Covaxin. The second dose of Covaxin should be after the 4th to 6th week of the first dose.

"There is no confusion. We all have to take 2 doses of Covishield and Covaxin doses in India," he said.

In India, the vaccination drive was started with Covaxin and Covishield on January 16, 2021. The second phase of COVID-19 vaccination to inoculate people above 60 years of age and those above 45 years with comorbities was started on March 1, 2021.

In the third phase that began on April 1, 2021, all above 45 years were included. In the next phase, which started on May 1, 2021, all adults above 18 years of age were included. Recently, Russia's Sputnik V has also been approved by the government for use in India.